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　We present two patients with idiopathic nephrotic syndrome who showed temporary 
indirect hyperbilirubinemia during the course of treatment with immunosuppressant 
drugs and/or  steroids. We analyzed the gene of the bilirubin uridine-diphosphate 
glucuronosyltransferase (B- UGT) and found that patient 1 was a compound 
heterozygote for the G71R and T-3263G mutations  and patient 2 was a heterozygote 
for the G71R mutation.  Hyperbilirubinemia should be  considered as one of the adverse 
effects of immunosuppressant drugs and/or steroids in patients carrying the 
polymorphic mutations of the B-UGT gene.
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INTRODUCTION
　Idiopathic nephrotic syndrome is a common 
renal disease in children.  The overall survival 
of patients with idiopathic nephrotic syndrome 
has markedly improved since steroids have 
been introduced into its treatment.  At present, 
steroids are recommended as the first choice 
for the treatment of idiopathic nephrotic 
syndrome in childhood. In spite of its effect-
iveness, long-term therapy sometimes causes 
adverse effects such as obesity, diabetes, peptic 
ulcers, osteoporosis, cataracts and glaucoma. 
In 1999, we reported that four patients with 
leukemia showed intermittent hyperbilirubi-
nemia during combined therapy consisting of 
steroids and other anti-leukemic agents1).  
They had the common mutation of the 
bilirubin uridine-diphosphate glucuronosyltra-
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nsferase (B-UGT) gene associated with Gilbert 
syndrome.  Gilbert  syndrome  is  common 
occurring in 2-12% of the population.  It is 
clinically characterized by mild unconjugated 
hyperbilirubinaemia in the absence of struc-
tural liver disease or haemolysis2). The G71R 
and (TA)7 mutations of the B-UGT gene are 
common among East Asians and Caucasians, 
respectively3),4).
　In this report, we present two unrelated 
patients with idiopathic nephrotic syndrome 
showing hyperbilirubinaemia during steroid 
therapy due to these common mutations of the 
B-UGT gene.
METHODS & MATERIALS
CASE REPORTS
Patient 1.  A 12-year-old girl developed neph-
rotic syndrome and was admitted to our 
hospital. She was treated with prednisolone 
(60mg/day) and her urinary protein was 
negative by the second week of administration.
She did not show any liver disease, and 
laboratory findings were normal, including 
ALT, AST, LDH, alkali phosphatase, γ-GTP, 
LAP and cholinesterase.  She did not have any 
hemolytic episodes and was serologically 
negative for hepatitis A, B and C. After 3 weeks 
of prednisolone therapy, she developed hyper-
bilirubineaemia (total bilirubin 1.4 -2.2mg/dl, 
direct bilirubin 0.2-0.3 mg/dl), which gradually 
decreased to normal range over the following 2 
weeks.  Her parents and younger brother were 
healthy and had no history of jaundice. 
Patient 2. A 22-year-old male was admitted to 
our hospital for the treatment of relapsed 
nephrotic syndrome.  When the patient was 11 
years of age, he developed nephrotic syndrome 
and was under prednisolone therapy. Two 
months later, he relapsed for the first time and 
underwent a percutaneous renal biopsy.  The 
biopsied specimens showed nephropathy with 
minimal change. Over the following 4 years, he 
frequently relapsed and received combined 
therapies consisting of steroid and immunosup-
pressants (mizoribine, cyclophosphamide, 
cyclosporin and chlorambucil). When he was 
under prednisolone therapy (40 mg/day) at our 
hospital, he showed hyperbilirubinaemia 
(serum total bilirubin 1.7mg/dl), which reduced
to normal range the following week.  He did 
not have any liver disease and exhibited 
normal levels of serum ALT (20 IU/L) AST (14 
IU/L), LDH (284 IU/L), alkali phosphatase 
(137 IU/L) and γ-GTP (8 IU/L).  He did not 
have any hemolytic episodes and was serologi-
cally negative for hepatitis A, B and C.  There 
was no history of jaundice in his family.
Analysis of the UDPGT1 gene
　Blood was collected after informed consent 
was obtained, and genomic DNA was extracted 
from the two patients by the standard 
procedure. Promoter and coding regions 
including exon-intron boundaries of the B-
UGT gene were amplified as four fragments by 
PCR and their sequences were determined 
according to methods reported in previous 
papers3),5).
RESULTS
　Direct sequencing revealed that patients 1 
and 2 were heterozygous for the Gly71Arg 
mutation (Fig.1A: data of patient 1 not shown). 
Patient 1 was also heterozygous for the T-
3263G mutation (Fig.1B).  They did not have 
any other mutations, including the (TA)7 
mutation. 
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DISCUSSION
　We reported two patients who presented 
temporary indirect hyperbilirubinemia by 
immunosuppresant drugs and/or prednisolone 
therapy for idiopathic nephrotic syndrome. 
They did not exhibit elevation of transami-
nases or hemolysis. Indirect hyperbilirubin-
emia has not been reported as a complication 
of nephrotic syndrome. Patients with nephrotic 
syndrome sometimes require intravenous 
albumin or plasma administration and have a 
risk for hepatitis viral infection.  However, our 
patients did not receive those administrations 
and were negative for hepatitis A, B and C.  As 
other possibilities, hepatic damage may be 
caused by chemical agents such as steroids or 
immunosuppresant drugs.  Fatty liver and the 
elevation of transaminases are well known as 
adverse effects of steroids. Immunosuppressant 
drugs also cause liver dysfunction and 
hyperbilirubinemia.  Our patients did not show 
liver dysfunction, however, these agents were 
probably associated with the hyperbilirubi-
nemia in our patients. Not all patients who 
receive these drugs always present hyperbiliru-
binemia, and some additional factors, including 
genetic factors, are likely required.  Polymor-
phisms of the genes encoding the enzymes 
involved in the drug metabolism are well 
known. In addition, people carrying polymor-
phic mutation of the B-UGT gene present 
intermittent hyperbilirubinemia under com-
bined therapy for leukemia1).  We studied the B-
UGT gene and found that patient 2 was a 
heterozygote for theG71R mutation and 
patient 1 was a compound heterozygote for the 
　Fig. 1. 
Sequence chromatography of the antisense chain of the patient 2 revealed a heterozygous mutation C-
to-T at nucleotide 211 (arrow), resulting in a G71R substitution (A). Sequence chromatography of the 
sense chain of the patient 1 showed a heterozygous T-to-G mutation at nucleotide-3263 (arrow) (B).
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G71R and T-3263G mutations.
　The G71R mutation of the B-UGT gene is 
common among Japanese, Koreans and 
Chinese3). Expression experiments showed that 
the G71R mutation had about 30% of the 
activity of wild type in homozygous state6).  
Recently, Sugatani, et al. reported that the T-
3263G mutation was associated with the 
majority of Gilbert's syndrome5).  The T-3263G 
mutation is located in the phenobarbital 
response enhancer module in the B-UGT gene 
and significantly decreases the transcriptional 
activity7). Plasma total bilirubin levels in 
compound heterozygotes for the T-3263G and 
(TA)7 or G71R mutations are significantly 
higher than in those with one or other of these 
mutations singly.  It is interesting to note that 
the plasma bilirubin level of the patient 1 was 
higher than that of patient 2. 
　Our patients did not have any episodes of 
hyperbilirubinemia. It is likely that the 
patients carrying these mutations can produce 
B-UGT enough to conjugate the bilirubin at 
steady state; however, they may not be able to 
metabolize the bilirubin under the stress of 
drug administrations.  The drugs may inhibit 
B-UGT activity or may impair the synthesis of 
B-UGT or may increase in the loading of 
unconjugated bilirubin.   
　Hyperbilirubinemia should be noted as one 
of the adverse effects of immunosuppressant 
drugs and /or steroids in the patients carrying 
the polymorphic mutations of the B-UGT gene 
in the treatment of nephrotic syndrome.
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